FDA: Avastin should not be used for breast cancer (Update)

December 16, 2010 By MATTHEW PERRONE , AP Health Writer

(AP) -- Federal health authorities are recommending the blockbuster drug Avastin no longer be used to treat breast cancer, saying recent studies failed to show the drug's original promise to help slow the disease.

The Food and Drug Administration's decision is supported by many cancer experts but is sure to draw resistance from cancer patients and some doctors who fiercely defend the drug and say it should remain available.

FDA officials stressed that the recommendation is only a preliminary step toward revoking the drug's approval for breast cancer. Swiss drugmaker Roche has refused to voluntarily withdraw the indication, and under law the company has 15 days to request a public meeting on the issue, according to the FDA.

"Today's decision was a difficult one for the agency but certainly not unique," said Dr. Janet Woodcock, director of FDA's drug center. "The FDA is responsible for assuring that the products we approve for patients are both effective and safe."

The FDA approved Avastin for breast cancer in 2008 based on studies suggesting it halted the spread of breast cancer for more than five months. But follow-up studies showed that the delay lasted no more than three months, and patients suffered dangerous side effects.

"Given the number of serious and life-threatening side effects, the FDA does not believe there is a favorable risk-to-benefit ratio," said Dr. Richard Pazdur, FDA's chief of cancer drug review.

In a separate announcement Thursday, the European Medicines Agency said it would keep the drug available for breast cancer.

If the FDA does revoke Avastin's breast cancer approval, doctors will still be able to prescribe the drug "off-label," though some insurers may not pay for it. For the time being, the FDA said the drug will remain available and patient care will not be affected.

The FDA's decision is a significant setback for the world's best-selling cancer drug and will likely cost drugmaker Roche hundreds of millions of dollars in lost revenue. Avastin is also approved for various types of colon, lung, kidney and brain cancer.

While vigorously opposed by thousands of cancer patients, the FDA's ruling is in line with the guidance of its outside panel of cancer experts, who voted 12-1 in July to rescind the drug's approval for breast cancer.

Cancer specialists said this week that Avastin never lived up to its initial promise.

"The bottom line is that it doesn't work very well," said Dr. Albert Braverman, chief of oncology at State University of New York Downstate Medical Center. "I've seen the occasional patient have a brief remission, which is nice, but it's certainly not doing anything important. It's not saving anyone's life."

But some patients credit their survival to Avastin and say the FDA's decision could amount to a death sentence.

Christi Turnage of Madison, Miss., said her cancer has been undetectable for more than two years since starting therapy with Avastin. She was diagnosed with breast cancer in June 2006 and began taking the drug in 2008 after the tumors spread, or metastized, to her lungs. Breast cancer that spreads to other parts of the body is generally considered incurable.

"It's a miracle drug for me and for several of my friends, and to deny it to women being diagnosed with metastatic disease is wrong," Turnage said. "We know it doesn't work for everybody but it works for a lot of us."

More than 9,500 cancer patients and friends and family signed a petition written by Turnage urging the FDA to keep Avastin approved.

Some doctors say the removal of the drug's approval could make it more difficult to study Avastin in some rare forms of breast cancer where it has not yet been tested.

"There is still significant interest among clinicians to determine if Avastin is useful in some subsets of breast cancer patients," said Dr. Elisa Port of Mount Sinai Medical Center in New York.


Related Stories

Recommended for you

New study reveals breast cancer cells recycle their own ammonia waste as fuel

October 19, 2017
Breast cancer cells recycle ammonia, a waste byproduct of cell metabolism, and use it as a source of nitrogen to fuel tumor growth, report scientists from Harvard Medical School in the journal Science.

US regulators approve 2nd gene therapy for blood cancer

October 19, 2017
U.S. regulators on Wednesday approved a second gene therapy for a blood cancer, a one-time, custom-made treatment for aggressive lymphoma in adults.

New findings explain how UV rays trigger skin cancer

October 18, 2017
Melanoma, a cancer of skin pigment cells called melanocytes, will strike an estimated 87,110 people in the U.S. in 2017, according to the Centers for Disease Control and Prevention. A fraction of those melanomas come from ...

Drug yields high response rates for lung cancer patients with harsh mutation

October 18, 2017
A targeted therapy resurrected by the Moon Shots Program at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries ...

Possible new immune therapy target in lung cancer

October 18, 2017
A study from Bern University Hospital in collaboration with the University of Bern shows that so-called perivascular-like cells from lung tumors behave abnormally. They not only inadequately support vascular structures, but ...

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Dec 16, 2010
There are too many "coincidences" for my liking in this Avistan/Genentech/Roche matter since 2008. Now, 2/3rds of this now Roche subsidiary business is rendered defunct by the negative FDA ruling today on Avistan. During this same time major members of Genentech's R&D brain-trust have found other jobs many outside of the hands-on tech sector.

Be those issues as they may be, my major concern boils down to this: When are there going to be significant discoveries in the cancer field comparable to those with HIV-AIDS that surge toward
prevention and treatments of cancers of all types which prolong life without virtually killing patients and reducing their quality of life such that death becomes their healthiest choice? That's the issue for me especially with regard to the American bio-research, medical and pharmaceutical industries. As it stands today in my opinion cancer research and treatment represents an appalling waste in most cases of public and private sector funds!

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.